News &
Media
-
ASX Small & Mid-Cap Conference: Neurotech International Limited
View More: ASX Small & Mid-Cap Conference: Neurotech International LimitedExecutive Director, Dr Tom Duthy presents Neurotech International at the ASX Small and Mid-Cap Conference on the 14th September, 2022. Watch the video recording here.
-
Neurotech International with Proactive at the ASX Small and Mid-Cap Conference
View More: Neurotech International with Proactive at the ASX Small and Mid-Cap ConferenceNeurotech International Executive Director Dr Tom Duthy speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022.
-
Cannabis extract has Autism success
View More: Cannabis extract has Autism success
-
New Hope for Children Living with Autism. Channel 7 NEWS 28 August 2022
View More: New Hope for Children Living with Autism. Channel 7 NEWS 28 August 2022 -
Neurotech International appoints industry expert during key phase of growth
View More: Neurotech International appoints industry expert during key phase of growthNeurotech International has made key appointments and changes to its board as it focuses on its developing and commercialising neurological solutions, including a cannabis breakthrough for paediatric autism.
-
Gerald Quigley, short discussion on 4RO Rockhampton regarding Autism
View More: Gerald Quigley, short discussion on 4RO Rockhampton regarding Autism -
Gerald Quigley, Co-host of The House of Wellness on 6PR discusses exciting new developments in Autism Spectrum Disorder (ASD) field linked to Cannabis, including a particular extract called NTI164.
View More: Gerald Quigley, Co-host of The House of Wellness on 6PR discusses exciting new developments in Autism Spectrum Disorder (ASD) field linked to Cannabis, including a particular extract called NTI164. -
Stocks Down Under Interview with Neurotech International (ASX:NTI)
View More: Stocks Down Under Interview with Neurotech International (ASX:NTI) -
Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism
View More: Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autismNeurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.